Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Galapagos NV ADR (GLPG)

Galapagos NV ADR (GLPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,905,082
  • Shares Outstanding, K 65,897
  • Annual Sales, $ 259,450 K
  • Annual Income, $ 229,120 K
  • 60-Month Beta 0.24
  • Price/Sales 7.42
  • Price/Cash Flow 45.77
  • Price/Book 0.65
Trade GLPG with:

Options Overview Details

View History
  • Implied Volatility 58.32% ( -11.00%)
  • Historical Volatility 15.52%
  • IV Percentile 96%
  • IV Rank 72.59%
  • IV High 73.47% on 04/16/24
  • IV Low 18.21% on 10/09/23
  • Put/Call Vol Ratio 4.00
  • Today's Volume 5
  • Volume Avg (30-Day) 29
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 2,121
  • Open Int (30-Day) 2,080

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year 0.43
  • Growth Rate Est. (year over year) -127.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.82 +0.31%
on 04/18/24
34.02 -15.02%
on 03/20/24
-4.50 (-13.47%)
since 03/18/24
3-Month
28.82 +0.31%
on 04/18/24
40.34 -28.33%
on 02/20/24
-8.93 (-23.60%)
since 01/18/24
52-Week
28.82 +0.31%
on 04/18/24
45.21 -36.05%
on 05/23/23
-8.55 (-22.82%)
since 04/18/23

Most Recent Stories

More News
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023

Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.

GSK : 39.27 (-0.83%)
PCRX : 26.10 (-2.50%)
GLPG : 28.91 (-1.06%)
VIR : 7.96 (-3.52%)
Does Galapagos NV (GLPG) Have the Potential to Rally 34% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 34.4% in Galapagos NV (GLPG). While the effectiveness of this highly sought-after metric is questionable, the positive...

GLPG : 28.91 (-1.06%)
Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround

Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...

GLPG : 28.91 (-1.06%)
Strength Seen in Galapagos NV (GLPG): Can Its 8% Jump Turn into More Strength?

Galapagos NV (GLPG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

GLPG : 28.91 (-1.06%)
MRNA : 102.00 (-1.39%)
Are Medical Stocks Lagging Galapagos (GLPG) This Year?

Here is how Galapagos NV (GLPG) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.

GLPG : 28.91 (-1.06%)
IMCR : 54.74 (+0.29%)
+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients

/PRNewswire/ -- The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as...

GLPG : 28.91 (-1.06%)
Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA

The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.

ACAD : 17.07 (-0.70%)
GLPG : 28.91 (-1.06%)
LPTX : 2.96 (-1.33%)
DTIL : 10.72 (-6.86%)
Wall Street Analysts See a 28% Upside in Galapagos NV (GLPG): Can the Stock Really Move This High?

The consensus price target hints at a 28.3% upside potential for Galapagos NV (GLPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

GLPG : 28.91 (-1.06%)
Is Galapagos (GLPG) Stock Outpacing Its Medical Peers This Year?

Here is how Galapagos NV (GLPG) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.

GLPG : 28.91 (-1.06%)
PDCO : 25.47 (-1.01%)
Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?

Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

GLPG : 28.91 (-1.06%)
HALO : 37.81 (-0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include...

See More

Key Turning Points

3rd Resistance Point 29.51
2nd Resistance Point 29.36
1st Resistance Point 29.13
Last Price 28.91
1st Support Level 28.75
2nd Support Level 28.60
3rd Support Level 28.37

See More

52-Week High 45.21
Fibonacci 61.8% 38.95
Fibonacci 50% 37.01
Fibonacci 38.2% 35.08
Last Price 28.91
52-Week Low 28.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar